# Study to Investigate the Safety/Tolerability and Pharmacokinetics/Pharmacodynamics of CKD-519

> **NCT02156544** · PHASE1 · COMPLETED · sponsor: **Chong Kun Dang Pharmaceutical** · enrollment: 41 (actual)

## Conditions studied

- Dyslipidemia

## Interventions

- **DRUG:** CKD-519
- **DRUG:** placebo

## Key facts

- **NCT ID:** NCT02156544
- **Lead sponsor:** Chong Kun Dang Pharmaceutical
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-06
- **Primary completion:** 2014-10
- **Final completion:** 2015-08
- **Target enrollment:** 41 (ACTUAL)
- **Last updated:** 2015-09-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02156544

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02156544, "Study to Investigate the Safety/Tolerability and Pharmacokinetics/Pharmacodynamics of CKD-519". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT02156544. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*